Search

Your search keyword '"Kristoferitsch W"' showing total 218 results
Start Over Author "Kristoferitsch W"
218 results on '"Kristoferitsch W"'

8. Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation: clinical and genetic characterization and target for therapy

Author

van Berge, Laura, Hamilton, Eline M., Linnankivi, Tarja, Uziel, Graziella, Steenweg, Marjan E., Isohanni, Pirjo, Wolf, Nicole I., Krägeloh-Mann, Ingeborg, Brautaset, Nils J., Andrews, P. Ian, de Jong, Brigit A., al Ghamdi, Malak, van Wieringen, Wessel N., Tannous, Bakhos A., Hulleman, Esther, Würdinger, Thomas, van Berkel, Carola G. M., Polder, Emiel, Abbink, Truus E. M., Struys, Eduard A., Scheper, Gert C., van der Knaap, Marjo S., Alehan, F., Appleton, R.E., Boltshauser, E., Brockmann, K., Calado, E., Carius, A., de Coo, I.F.M., van Coster, R., El-Zind, S., Erturk, O., Fadeeva, L., Feigenbaum, A., Gökben, S., Gorman, M., Gulati, S., Hnĕvsová, P., Joost, K., Köhler, W., Kolk, A, Kristoferitsch, W., Lemos Silveira, E., Lin, J., Lutz, S., Mendonça, C., Nuttin, C., Opladen, T., Savoiardo, M., Schiffmann, R., Seitz, A., Serkov, S., Sharma, S., Stockler, S., Temple, I.K., Uluc, K., Vojta, S., Wilms, G., Wong, B., and Yapici, Z.

Published
2014
Full Text
View/download PDF

9. Acute Cerebrovascular Disease in the Young: The Stroke in Young Fabry Patients Study

Author

Rolfs, Arndt, Fazekas, Franz, Grittner, Ulrike, Dichgans, Martin, Martus, Peter, Holzhausen, Martin, Böttcher, Tobias, Heuschmann, Peter U., Tatlisumak, Turgut, Tanislav, Christian, Jungehulsing, Gerhard J., Giese, Anne-Katrin, Putaala, Jukaa, Huber, Roman, Bodechtel, Ulf, Lichy, Christoph, Enzinger, Christian, Schmidt, Reinhold, Hennerici, Michael G., Kaps, Manfred, Kessler, Christof, Lackner, Karl, Paschke, Eduard, Meyer, Wolfgang, Mascher, Hermann, Riess, Olaf, Kolodny, Edwin, Norrving, Bo, Rolfs, A, Ginsberg, M, Hennerici, MG, Kessler, C, Kolodny, E, Martus, P, Norrving, B, Ringelstein, EB, Rothwell, PM, Venables, G, Bornstein, N, deDeyn, P, Dichgans, M, Fazekas, F, Markus, H, Rie, O, Biedermann, C, Böttcher, T, Brüderlein, K, Burmeister, J, Federow, I, König, F, Makowei, G, Niemann, D, Rolfs, A, Rösner, S, Zielke, S, Grittner, U, Martus, P, Holzhausen, M, Fazekas, F, Enzinger, C, Schmidt, R, Ropele, S, Windisch, M, Sterner, E, Bodamer, O, Fellgiebel, A, Hillen, U, Jonas, L, Kampmann, C, Kropp, P, Lackner, K, Laue, M, Mascher, H, Meyer, W, Paschke, E, Weidemann, F, Berrouschot, J, Stoll, A, Rokicha, A, Sternitzky, C, Thomä, M, DeDeyn, PP, Sheorajpanday, R, De Brabander, I, Yperzeele, L, Brouns, R, Oschmann, P, Pott, M, Schultes, K, Schultze, C, Hirsekorn, J, Jungehulsing, GJ, Villringer, A, Schmidt, W, Liman, T, Nowe, T, Ebinger, M, Wille, A, Loui, H, Objartel, A, übelacker, A, Mette, R, Jegzentis, K, Nabavi, DG, Crome, O, Bahr, D, Ebke, M, Platte, B, Kleinen, C, Mermolja Gunther, K, Heide, W, Pape, O, Hanssen, JR, Stangenberg, D, Klingelhofer, J, Schmidt, B, Schwarz, S, Schwarze, J, Frandlih, L, Iwanow, J, Steinbach, I, Krieger, D, Boysen, G, Leth Jeppesen, L, Petersen, A, Reichmann, H, Becker, U, Dzialkowski, I, Hentschel, H, Lautenschlager, C, Hanso, H, Gahn, G, Ziemssen, T, Fleischer, K, Sehr, B, McCabe, DJH, Tobin, O, Kinsella, J, Murphy, RP, Jander, S, Hartung, HP, Siebler, M, Bottcher, C, Kohne, A, Platzen, J, Brosig, TC, Rothhammer, V, Henseler, C, Neumann-Haefelin, T, Singer, OC, Ermis, U, dos Santos, IMRM, Schuhmann, C, van de Loo, S, Kaps, M, Allendorfer, J, Tanislav, C, Brandtner, M, Muir, K, Dani, K, MacDougall, N, Smith, W, Rowe, A, Welch, A, Fazekas, F, Schrotter, G, Krenn, U, Horner, S, Pendl, B, Pluta-Fuerst, A, Trummer, U, Kessler, C, Chatzopoulos, M, v Sarnowski, Bettina, Schminke, Ulf, Link, T, Khaw, A, Nieber, E, Zierz, S, Muller, T, Wegener, N, Wartenberg, K, Gaul, C, Richter, D, Rosenkranz, M, Krützelmann, AC, Hoppe, J, Choe, CU, Narr, S, Magnus, TU, Thomalla, G, Leypoldt, F, Otto, D, Lichy, C, Hacke, W, Barrows, RJ, Tatlisumak, T, Putaala, J, Curtze, S, Metso, M, Willeit, J, Furtner, M, Spiegel, M, Knoflach, MH, Prantl, B, Witte, OW, Brämer, D, Günther, A, Prell, T, Herzau, C, Aurich, K, Deuschl, G, Wodarg, F, Zimmermann, P, Eschenfelder, CC, Levsen, M, Weber, JR, Marecek, SM, Schneider, D, Michalski, D, Kloppig, W, Küppers-Tiedt, L, Schneider, M, Schulz, A, Matzen, P, Weise, C, Hobohm, C, Meier, H, Langos, R, Urban, D, Gerhardt, I, Thijs, V, Lemmens, R, Marcelis, E, Hulsbosch, C, Aichner, F, Haring, HP, Bach, E, Machado Candido, J, e Silva, AA, Lourenco, M, de Sousa, AIM, Derex, L, Cho, TH, Díez-Tejedor, E, Fuentes, B, Martínez-Sanchez, P, Pérez-Guevara, MI, Hamer, H, Metz, A, Hallenberger, K, Müller, P, Baron, P, Bersano, A, Gattinoni, M, Vella, N, Mallia, M, Jauss, M, Adam, L, Heidler, F, Gube, C, Kiszka, M, Dichgans, M, Karpinska, A, Mewald, Y, Straub, V, Dörr, A, Zollver, A, Ringelstein, EB, Schilling, M, Borchert, A, Preuth, N, Duning, T, Kuhlenbäumer, G, Schulte, D, Rothwell, PM, Marquardt, L, Schlachetzki, F, Boy, S, Mädl, J, Ertl, GM, Fehm, NPR, Stadler, C, Benecke, R, Dudesek, A, Kolbaske, S, Lardurner, G, Sulzer, C, Zerbs, A, Lilek, S, Walleczek, AM, Sinadinowska, D, Janelidze, M, Beridze, M, Lobjanidze, N, Dzagnidze, A, Melms, A, Horber, K, Fink, I, Liske, B, Ludolph, AC, Huber, R, Knauer, K, Hendrich, C, Raubold, S, Czlonkowska, A, Baranowska, A, Blazejewska-Hyzorek, B, Lang, W, Kristoferitsch, W, Ferrari, J, Ulrich, E, Flamm-Horak, A, Lischka-Lindner, A, Schreiber, W, Demarin, V, Tranjec, Z, Bosner-Puretic, M, Jurašić, MJ, Basic Kes, V, Budisic, M, and Kopacevic, L

Published
2013
Full Text
View/download PDF

20. To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis - Authors reply

Author

Dessau, R. B., van Dam, A. P., Fingerle, V., Gray, J., Hovius, J. W., Hunfeld, K. -P., Jaulhac, B., Kahl, O., Kristoferitsch, W., Lindgren, Per-Eric, Markowicz, M., Mavin, S., Ornstein, K., Rupprecht, T., Stanek, G., Strle, F., Dessau, R. B., van Dam, A. P., Fingerle, V., Gray, J., Hovius, J. W., Hunfeld, K. -P., Jaulhac, B., Kahl, O., Kristoferitsch, W., Lindgren, Per-Eric, Markowicz, M., Mavin, S., Ornstein, K., Rupprecht, T., Stanek, G., and Strle, F.

Abstract

n/a

Published
2018
Full Text
View/download PDF

21. To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis: a position paper of ESGBOR, the ESCMID study group for Lyme borreliosis

Author

Dessau, R. B., van Dam, A. P., Fingerle, V., Gray, J., Hovius, J. W., Hunfeld, K-P, Jaulhac, B., Kahl, O., Kristoferitsch, W., Lindgren, Per-Eric, Markowicz, M., Mavin, S., Ornstein, K., Rupprecht, T., Stanek, G., Strle, F., Dessau, R. B., van Dam, A. P., Fingerle, V., Gray, J., Hovius, J. W., Hunfeld, K-P, Jaulhac, B., Kahl, O., Kristoferitsch, W., Lindgren, Per-Eric, Markowicz, M., Mavin, S., Ornstein, K., Rupprecht, T., Stanek, G., and Strle, F.

Abstract

Background: Lyme borreliosis (LB) is a tick-borne infection caused by Borrelia burgdorferi sensu lato. The most frequent clinical manifestations are erythema migrans and Lyme neuroborreliosis. Currently, a large volume of diagnostic testing for LB is reported, whereas the incidence of clinically relevant disease manifestations is low. This indicates overuse of diagnostic testing for LB with implications for patient care and cost-effective health management. Aim: The recommendations provided in this review are intended to support both the clinical diagnosis and initiatives for a more rational use of laboratory testing in patients with clinically suspected LB. Sources: This is a narrative review combining various aspects of the clinical and laboratory diagnosis with an educational purpose. The literature search was based on existing systematic reviews, national and international guidelines and supplemented with specific citations. Implications: The main recommendations according to current European case definitions for LB are as follows. Typical erythema migrans should be diagnosed clinically and does not require laboratory testing. The diagnosis of Lyme neuroborreliosis requires laboratory investigation of the spinal fluid including intrathecal antibody production, and the remaining disease manifestations require testing for serum antibodies to B. burgdorferi. Testing individuals with non-specific subjective symptoms is not recommended, because of a low positive predictive value. (C) 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved., Funding Agencies|EU INTERREG OKS

Published
2018
Full Text
View/download PDF

22. To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis – Author's reply

Author

Dessau, R.B., primary, van Dam, A.P., additional, Fingerle, V., additional, Gray, J., additional, Hovius, J.W., additional, Hunfeld, K.-P., additional, Jaulhac, B., additional, Kahl, O., additional, Kristoferitsch, W., additional, Lindgren, P.-E., additional, Markowicz, M., additional, Mavin, S., additional, Ornstein, K., additional, Rupprecht, T., additional, Stanek, G., additional, and Strle, F., additional

Published
2018
Full Text
View/download PDF

24. Mutations in the gene tripeptidyl peptidase II (TPP2) and multiple sclerosis

Author

Reinthaler, E. M., Graf, E., Zrzavy, T., Wieland, T., Hotzy, C., Kopecky, C., Schmied, C., Leutmezer, F., Keilani, M., Lill, C. M., Hoffjan, S., Epplen, J. T., Zettl, U. K., Hecker, M., Deutschlaender, A., Ahram, M., Mustafa, B., El-Khateeb, M., Vilarino-Guell, C., Sadovnick, D. A., Zimprich, F., Tomkinson, B, Strom, T. M., Kristoferitsch, W., Lassmann, H., Zimprich, A., Reinthaler, E. M., Graf, E., Zrzavy, T., Wieland, T., Hotzy, C., Kopecky, C., Schmied, C., Leutmezer, F., Keilani, M., Lill, C. M., Hoffjan, S., Epplen, J. T., Zettl, U. K., Hecker, M., Deutschlaender, A., Ahram, M., Mustafa, B., El-Khateeb, M., Vilarino-Guell, C., Sadovnick, D. A., Zimprich, F., Tomkinson, B, Strom, T. M., Kristoferitsch, W., Lassmann, H., and Zimprich, A.

Published
2016

25. Kidney transplantation in patients with Fabry disease

Author

Cybulla M, Walter KN, Schwarting A, Divito R, Feriozzi S, Sunder Plassmann G, Binder C, Kotanko P, Kroepfl T, Plecko B, Bodamer O, Hauser AC, Kleinert J, Kristoferitsch W, Schreiber W, Georges B, Nassogne MC, Pirson Y, Dehout F, Henry F, Roland D, Vauthier L, Goyens P, Mazoin N, Van Maldergem L, Eyskens F, Bultas J, Karetová D, Linhart A, Dostalova G, Choukroun G, Berthelot J, Hardy P, Carey Reomonnay S, Lacombe D, Bataille P, Benziane S, Mittelberger JM, Thevenot C, Dobbelaere D, Hachulla E, Dussol B, Reade R, Khau van Kien A, Kaminsky P, Guyot C, Lino M, Ghafari T, Germain DP, Knebelmann B, Lidove O, Ouali N, Touati G, Monlun E, Jaussaud R, Richalet B, Klotz V, Andres E, Caraman D, Bazex J, Perrichot R, Hennermann J, von Arnim Baas A, Stolz S, Hoffmann B, Chrobot E, Grabbe S, Jansen T, Neumann HP, Schluh G, Gal A, Muschol N, Shäfer E, Ullrich K, Das A, Illsinger S, Lücke T, Bähner F, Baron K, Beck M, Bruns K, Delgado Sanchez S, Hartung R, Kalkum G, Kampmann C, Keilmann A, Lackner K, Pitz S, Whybra C, Wiethoff C, Koletzko B, Pontz B, Böttcher T, Miethe S, Rolfs A, Davydenko I, Wanner C, Maródi L, Gabrielli O, Gobbi S, Concolino D, Zampetti A, Borsini W, Buchner S, Menni F, Parini R, Ravaglia R, Santus F, Di Vito R, Burlina A, Burlina AP, Manara R, Antuzzi D, Castorina M, Ricci R, Kaarbøe Ø, Skarbøvik A, Houge G, Svarstad E, Tøndel C, Barba MA, Botella R, Franco A, Torras J, Gómez Huertas E, Torregrosa V, Fernández V, Paniagua J, Rodriguez F, Herrera J, Febrer I, Perez Garcia A, Martin I, Barbado FJ, Garcia de Lorenzo A, López M, González J, Ballarin J, Torra R, Hernández S, Ara J, Bonal J, Pintos G, Andreu J, Rivera A, Oqvist B, Huyen Do U, Barbey F, Hayoz D, Theytaz J, Schärer M, Schulthess G, Steinmann B, Walter K, Widmer U, Hollak C, Ormel E, van Duinen A, Vetter A, Corcoran M, Cox TM, Deegan P, Ramaswami U, Wright N, Baker R, Blincoe M, Bruce R, Burns A, Close L, Davey C, Elliott J, Elliott P, Evans S, Ginsberg L, Hajioff D, Hughes D, Ioannidis A, Keshav S, Mehta A, Milligan A, Orteu C, Richfield L., STRISCIUGLIO, PIETRO, Cybulla, M, Walter, Kn, Schwarting, A, Divito, R, Feriozzi, S, Sunder Plassmann, G, Binder, C, Kotanko, P, Kroepfl, T, Plecko, B, Bodamer, O, Hauser, Ac, Kleinert, J, Kristoferitsch, W, Schreiber, W, Georges, B, Nassogne, Mc, Pirson, Y, Dehout, F, Henry, F, Roland, D, Vauthier, L, Goyens, P, Mazoin, N, Van Maldergem, L, Eyskens, F, Bultas, J, Karetová, D, Linhart, A, Dostalova, G, Choukroun, G, Berthelot, J, Hardy, P, Carey Reomonnay, S, Lacombe, D, Bataille, P, Benziane, S, Mittelberger, Jm, Thevenot, C, Dobbelaere, D, Hachulla, E, Dussol, B, Reade, R, Khau van Kien, A, Kaminsky, P, Guyot, C, Lino, M, Ghafari, T, Germain, Dp, Knebelmann, B, Lidove, O, Ouali, N, Touati, G, Monlun, E, Jaussaud, R, Richalet, B, Klotz, V, Andres, E, Caraman, D, Bazex, J, Perrichot, R, Hennermann, J, von Arnim Baas, A, Stolz, S, Hoffmann, B, Chrobot, E, Grabbe, S, Jansen, T, Neumann, Hp, Schluh, G, Gal, A, Muschol, N, Shäfer, E, Ullrich, K, Das, A, Illsinger, S, Lücke, T, Bähner, F, Baron, K, Beck, M, Bruns, K, Delgado Sanchez, S, Hartung, R, Kalkum, G, Kampmann, C, Keilmann, A, Lackner, K, Pitz, S, Whybra, C, Wiethoff, C, Koletzko, B, Pontz, B, Böttcher, T, Miethe, S, Rolfs, A, Davydenko, I, Wanner, C, Maródi, L, Gabrielli, O, Gobbi, S, Concolino, D, Strisciuglio, Pietro, Zampetti, A, Borsini, W, Buchner, S, Menni, F, Parini, R, Ravaglia, R, Santus, F, Di Vito, R, Burlina, A, Burlina, Ap, Manara, R, Antuzzi, D, Castorina, M, Ricci, R, Kaarbøe, Ø, Skarbøvik, A, Houge, G, Svarstad, E, Tøndel, C, Barba, Ma, Botella, R, Franco, A, Torras, J, Gómez Huertas, E, Torregrosa, V, Fernández, V, Paniagua, J, Rodriguez, F, Herrera, J, Febrer, I, Perez Garcia, A, Martin, I, Barbado, Fj, Garcia de Lorenzo, A, López, M, González, J, Ballarin, J, Torra, R, Hernández, S, Ara, J, Bonal, J, Pintos, G, Andreu, J, Rivera, A, Oqvist, B, Huyen Do, U, Barbey, F, Hayoz, D, Theytaz, J, Schärer, M, Schulthess, G, Steinmann, B, Walter, K, Widmer, U, Hollak, C, Ormel, E, van Duinen, A, Vetter, A, Corcoran, M, Cox, Tm, Deegan, P, Ramaswami, U, Wright, N, Baker, R, Blincoe, M, Bruce, R, Burns, A, Close, L, Davey, C, Elliott, J, Elliott, P, Evans, S, Ginsberg, L, Hajioff, D, Hughes, D, Ioannidis, A, Keshav, S, Mehta, A, Milligan, A, Orteu, C, and Richfield, L.

Published
2009

26. Double-blind randomized multicenter dose-comparison study of interferon-β-1a (AVONEX): rationale, design and baseline data

Author

Kristoferitsch, W, Seeldrayers, P, Kyriallis, K, Brochet, B, Confavreux, C, Clanet, M, Cesaro, P, Defer, G, Edan, G, Lyon-Caen, O, Pelletier, J, Rumbach, L, Roullet, E, Vermersch, P, Dengler, R, Zschenderlein, R, Storch-Hagenlocher, B, Sailer, M, Hohlfeld, R, Kunze, KP, Heesen, C, Bamborschke, P, Grunwald, F, Hartung, HP, Rieckmann, P, DeKeyser, J, Montalban, [No Value], Fernandez, U, Arbizu, T, Sandberg, M, Kappos, L, Bates, D, Campbell, MJ, Capildeo, R, Compston, A, McLellan, DL, Wroe, S, Young, C, Radue, EW, Polman, C, Kesselring, J, Thompson, A, Wekerle, H, and Whitehead, J

Subjects
Adult, Male, interferon-beta-1a, Multiple Sclerosis, Interferon-beta, MRI follow-up, Middle Aged, Magnetic Resonance Imaging, dose-comparison study design, 03 medical and health sciences, 0302 clinical medicine, Adjuvants, Immunologic, Double-Blind Method, Neurology, MAGNETIC-RESONANCE, Humans, Multicenter Studies as Topic, Female, 030212 general & internal medicine, Neurology (clinical), RELAPSING MULTIPLE-SCLEROSIS, Interferon beta-1a, 030217 neurology & neurosurgery, Follow-Up Studies, Randomized Controlled Trials as Topic
Abstract

We describe the rationale and design of a double-blind, randomized multicenter, dose-comparison study of interferon-beta-Ia (IFN-beta -Ia: AVONEX(R) in the treatment of relapsing multiple sclerosis (MS). The study is expected to provide quantitative insights on the dose range for optimal clinical benefits in MS. The study involves 802 patients in 10 European countries who have EDSS scores 2.0-5.5, and who have experienced at least two relapses within the 3 years prior to enrolment Patients ore randomized to receive once-weekly intramuscular injections of IFN-beta -Ia 30 or 60 mcg for at least 3 years. The primary endpoint of the study is the effect of IFN-beta -Ia therapy on the time to sustained progression of disability. For patients with a baseline EDSS less than or equal to 4.5, sustained progression of disability is defined as a I point increase in EDSS from baseline, maintained for 6 months. For patients with baseline EDSS less than or equal to 5, sustained progression of disability is defined as reaching on EDSS greater than or equal to 6.0 maintained for 6 months. EDSS scores will be determined every 3 months. A series of prospectively defined secondary and tertiary efficacy endpoints will be examined Safety will be monitored throughout the study. Magnetic resonance imaging (MRI) with and without gadolinium-enhancement has been Performed in at least 358 patients at baseline and repeated annually after enrolment In a subset of these patients, a frequent MRI study is also being performed.

Published
2001

34. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study

Author

Clanet, M., Kappos, L., Hartung, H.P., Hohlfeld, R., Kristoferitsch, W., Schrieber, A., Schlederer, A., Seeldrayers, P., Piette, A., Papacostas, S., Kyriallis, K., Pantzaris, A., Brochet, B., Gayou, A., Rouanet, M., Rouant, F., Confavreux, C., Riche, G., Blanc, S., Achiti, J., Magnier, C., Aubertin, P., Mekies, C., Brassat, D., Thalamas, C., Vuilleman, C., Senard, A., Lau, G., Cesaro, P., Degos, F., Defer, G., Schaeffer, S., Edan, G., de Marco, A., Cahagne, V., Belliard, S., Lyon-Caen, O., Stankoff, B., Lubetzki, C., Arnulf, I., Damier, P., Pelletier, J., Tamman, D., Suchet, L., Dalecky, A., Rumbach, L., Moulin, A., Berger, E., Roullet, E., Pez, D., Heinzlef, O., Lecanuet, P., Vermersch, P., Engles, A., Dengler, R., Heidenreich, F., Lindert, A., Koehler, A., Windhagen, A., Steiner, A., Zschenderlein, R., Luenemann, J., Gelderblom, H., Kassim, N., Storch-Hagenlocher, B., Koerner, A., Vogt-Schaden, A., Stingle, A., Storch-Hagenlocher, A., Sailer, 27449, Matzke, A., Dose, A., Weiler, C., Kunze, K., Heesen, C., Bamborschke, P., Petereit, H., Liu, A., Nolden, A., Grunwald, F., Menck, A., Grupe, A., Rieckmann, P., Weilbach, A., Flachenecker, A., Chan, A., Maurer, A., de Keyser, Jacques, Zwanniken, G., Zorgdrager, A., Montalban, X., Nos, A., Fernandez, O., Tamayo, J.A., Romero, F., Arbizu, T., Martinez-Yelamos, A., Martin, A, and Casado, A.

Subjects
Adult, Male, medicine.medical_specialty, Injections, Intramuscular, Central nervous system disease, 03 medical and health sciences, Disability Evaluation, 0302 clinical medicine, Multiple Sclerosis, Relapsing-Remitting, Adjuvants, Immunologic, Internal medicine, Epidemiology, Clinical endpoint, medicine, Humans, 030212 general & internal medicine, Clinical efficacy, business.industry, Incidence (epidemiology), Multiple sclerosis, Interferon beta-1a, Interferon-beta, medicine.disease, Surgery, Europe, Interferon β 1a, Treatment Outcome, Neurology, Disease Progression, Female, Neurology (clinical), business, 030217 neurology & neurosurgery, medicine.drug, Follow-Up Studies
Abstract

Background: Multiple sclerosis (MS) is a chronic disease requiring long-term monitoring of treatment. Objective: To assess the four-year clinical efficacy of intramuscular (IM) IFNb-1a in patients with relapsing MS from the European IFNb-1a Dose-C omparison Study. Methods: Patients who completed 36 months of treatment (Part 1) of the European IFNb-1a Dose-C omparison Study were given the option to continue double-blind treatment with IFNb-1a 30 mcg or 60 mcg IM once weekly (Part 2). Analyses of 48-month data were performed on sustained disability progression, relapses, and neutralizing antibody (NA b) formation. Results: O f 608/802 subjects who completed 36 months of treatment, 493 subjects continued treatment and 446 completed 48 months of treatment and follow-up. IFNb-1a 30 mcg and 60 mcg IM once weekly were equally effective for up to 48 months. There were no significant differences between doses over 48 months on any of the clinical endpoints, including rate of disability progression, cumulative percentage of patients who progressed (48% and 43%, respectively), and annual relapse rates; relapses tended to decrease over 48 months. The incidence of patients who were positive for NAbs at any time during the study was low in both treatment groups. Conclusion: C ompared with 60-mcg IM IFNb-1a once weekly, a dose of 30 mcg IM IFNb-1a once weekly maintains the same clinical efficacy over four years.

Published
2004

35. Die zerebral enthemmte Blase

Author

Kristoferitsch W

Subjects
Neurologie, Gesellschaft für Inkontinenzhilfe Österreich, GIHÖ, Urologie, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, Harninkontinenz
Published
2004

36. International consensus statement on the use of disease-modifying agents in multiple sclerosis

Author

Freedman*, Ms, 1, Blumhardt2, Ld, Brochet3, B., Comi4, G., Noseworthy5, Jh, Sandberg Wollheim6, M., Soelberg Sørensen 7and the Paris Workshop This consensus statement was endorsed by: LD Blumhardt, P., Brochet, B., Comi, G., Correale, J., Cristiano, E., Fernandez, O., Freedman, Ms, Stfm, Frequin, Gallo, Paolo, Garcia Merino, A., Gebeily, S., Heesen, C., King, J., Kristoferitsch, W., Kyritsis, Ap, Lander, R., Leite, I., Pck, Li, Lublin, Fd, Macias, Ma, Miller, A., Milonas, I., Noseworthy, Jh, Oger, J., Bkc, Ong, Pedrosa, R., Po ̈hlau, D., Pollard, Jd, Pozzilli, C., Reder, At, Rieckmann, P., Roullet, E., Sandberg Wollheim, M., Schlesinger, A., Siva, A., Soelberg Sørensen, P., Trojano, M., Vollmer, T., Wolinsky, Js, and Zettl, U.

Published
2002

37. Double-blind randomized multicenter dose-comparison study of interferon-beta-1a (AVONEX): rationale, design and baseline data

Author

De Keyser, Jacques, Kristoferitsch, W., Seeldrayers, P., Kyriallis, K., Anderson, D., Liddiard, S., Keane, R., and Gerontology

Abstract

We describe the rationale and design of a double-blind, randomized, multicenter, dose-comparison study of interferon-beta-1a (IFN-beta-1a; AVONEX), in the treatment of relapsing multiple sclerosis (MS). The study is expected to provide quantitative insights on the dose range for optimal clinical benefits in MS. The study involves 802 patients in 10 European countries who have EDSS scores 2.0-5.5, and who have experienced at least two relapses within the 3 years prior to enrolment Patients are randomized to receive once-weekly intromuscular injections of IFN-beta-la 30 or 60 mcg for at least 3 years. The primary endpoint of the study is the effect of IFN-beta-1a therapy on the time to sustained progression of disability. For patients with a baseline EDSS or = 5, sustained progression of disability is defined as reaching an EDSS > or = 6.0, maintained for 6 months. EDSS scores will be determined every 3 months. A series of prospectively defined secondary and tertiary efficacy endpoints will be examined. Safety will be monitored throughout the study. Magnetic resonance imaging (MRI) with and without gadolinium-enhancement has been performed in at least 358 patients at baseline and repeated annually after enrolment In a subset of these patients, a frequent MRI study is also being performed

Published
2001

40. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature

Author

Jarius, S, primary, Paul, F, additional, Franciotta, D, additional, de Seze, J, additional, Münch, C, additional, Salvetti, M, additional, Ruprecht, K, additional, Liebetrau, M, additional, Wandinger, KP, additional, Akman-Demir, G, additional, Melms, A, additional, Kristoferitsch, W, additional, and Wildemann, B, additional

Published
2011
Full Text
View/download PDF

44. POSTER ABSTRACTS

Author

Bekri, S, primary, Clarke, J, additional, De Meirleir, L, additional, Feriozzi, S, additional, Houge, G, additional, Kristoferitsch, W, additional, and Pastores, G, additional

Published
2007
Full Text
View/download PDF

45. Konsensusempfehlungen zur symptomatischen Therapie der Multiplen Sklerose

Author

Henze, T, primary, Albrecht, H, additional, Feneberg, W, additional, Haas, J, additional, Haupts, M, additional, Kesselring, J, additional, König, N, additional, Kristoferitsch, W, additional, Mauritz, KH, additional, Pette, M, additional, Pöllmann, W, additional, Rieckmann, P, additional, Seidel, D, additional, Starck, M, additional, Steinbrecher, A, additional, Voltz, R, additional, Zettl, UK, additional, and Toyka, KV, additional

Published
2004
Full Text
View/download PDF

48. Apolipoprotein E 4 is associated with rapid progression of multiple sclerosis

Author

Fazekas, F., primary, Strasser-Fuchs, S., additional, Kollegger, H., additional, Berger, T., additional, Kristoferitsch, W., additional, Schmidt, H., additional, Enzinger, C., additional, Schiefermeier, M., additional, Schwarz, C., additional, Kornek, B., additional, Reindl, M., additional, Huber, K., additional, Grass, R., additional, Wimmer, G., additional, Vass, K., additional, Pfeiffer, K. H., additional, Hartung, H. P., additional, and Schmidt, R., additional

Published
2001
Full Text
View/download PDF

50. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature.

Author

Jarius, S, Paul, F, Franciotta, D, de Seze, J, Münch, C, Salvetti, M, Ruprecht, K, Liebetrau, M, Wandinger, KP, Akman-Demir, G, Melms, A, Kristoferitsch, W, and Wildemann, B

Subjects
MYASTHENIA gravis, NEUROMUSCULAR diseases, CAUCASIAN race, AUTOIMMUNE diseases, IMMUNOGLOBULINS, DISEASES
Abstract

The article presents a study which aims to report 10 cases of Caucasian patients with myasthenia gravis (MG) and neuromyelitis optica (NMO). The study is a restrospective research which analyzes NMO diagnosed among patients based on the 2006 revised diagnostic criteria. Results of the study show autoimmune disorders or autoimmune antibodies that co-exist in 17 patients out of 26 patients sampled.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results